Gilead Sciences, Inc.

Global biopharma anchored by dominant HIV franchise (Biktarvy, Descovy, lenacapavir). Expanding into oncology via Kite Pharma CAR-T franchise (Yescarta, Tecartus) and Trodelvy (TROP2 ADC). Liver disease portfolio includes hepatitis C/B/D cures and NASH pipeline.

• monetization model: Product sales of branded prescription drugs (~99% of total revenues); royalties/contract/other ~1%. No subscription/SaaS. [10-K FY2023, Business & Note 2 Revenues] sec.gov (Acc. 0000882095-24-000010; FY2023 latest available in my knowledge)
• revenue mix: FY2023 product sales $26,866M: HIV $18,175M (~68%), Oncology $2,936M (~11%), Liver Disease $2,784M (~10%), Veklury $2,184M (~8%), Other $787M (~3%); royalty/contract/other $250M. [10-K FY2023, Note 2 Revenues]
• who pays: Direct buyers are wholesale distributors/specialty pharmacies; ultimate reimbursement via payers/insurers, Medicare/Medicaid/VA, patients. [10-K FY2023, Business]
• margin_value_capture: FY2023 gross margin ~77% (gross profit $20,909M/$27,116M); operating margin ~32% ($8,745M). Value accrues to IP/patents and manufacturing. [10-K FY2023, Financial Statements]

• customer classes: Health Systems & Providers, Payers & Insurers, wholesale distributors & specialty pharmacies, government agencies. [10-K FY2023, Business]

Gilead Sciences, Inc. is a research-based biopharmaceutical company. Its SEC EDGAR company page is:

• GILD SEC EDGAR filings index:

sec.gov

Gilead’s revenue is primarily generated from product sales of antiviral and oncology therapeutics. The main reported product categories in recent periods are:

• HIV — including Biktarvy, Descovy, Odefsey, Genvoya, Sunlenca, and older agents.
• Liver disease — including Vemlidy, Vosevi, Epclusa, Harvoni.
• Oncology — including Trodelvy, Yescarta, Tecartus, Zydelig.
• Other/COVID-19 — primarily Veklury/remdesivir, which has been declining from pandemic peaks.

Exact segment revenue mix percentages are needs primary source validation because they must be read from the applicable 10-K or 10-Q revenue disaggregation. Prior-period rough share estimates from memory are deliberately omitted to avoid fabrication.

Gilead sells patented prescription drugs through wholesalers/distributors, specialty pharmacies, retail pharmacies, hospitals, and government purchasers. Revenue is recognized when control transfers to the customer, but net revenue reflects gross-to-net deductions: rebates, chargebacks, Medicaid/Medicare rebates, 340B discounts, copay assistance, and distributor fees. This is standard for the industry, but the exact revenue-recognition language and gross-to-net percentages must be read from the filing; those percentages are needs primary source validation.

Patented small-molecule and biologic products generally support high gross margins; Gilead’s exact gross margin, operating margin, and R&D intensity are needs primary source validation and must be calculated from the income statement in the latest 10-K.

Payers include commercial insurers, Medicare, Medicaid, the Department of Veterans Affairs, AIDS Drug Assistance Programs, international health systems, and patients via copays. The company’s own 10-K risk factors and MD&A discuss payer concentration and pricing pressure; specific payer mix percentages are needs primary source validation.

Because I could not access the most recent 10-K directly, I will not name top customers from memory. Public 10-K disclosures sometimes identify major wholesale distributors, but those names must be read from the filing itself. This item remains needs primary source validation.

Customer classes include:

• Wholesalers/distributors
• Retail and specialty pharmacies
• Hospitals and infusion centers
• Government purchasers: Medicare, Medicaid, VA, AIDS Drug Assistance Programs
• International health systems and payers

Specific buyer archetypes and named customers must come from the filing’s revenue and significant-customer disclosures. I could not verify those names in this environment, so I am not listing specific customer names. That item is needs primary source validation.

Intervene layer (Context). HIV franchise is a durable cash-flow engine — Biktarvy has patent protection into the 2030s and lenacapavir (twice-yearly injectable) extends the moat. Oncology buildout via Kite CAR-T diversifies beyond antivirals. Best-in-class margins (79% GM) and high institutional ownership signal quality. The toll-road customer that keeps spending on manufacturing and delivery infrastructure.